Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 882796 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $9.53Day −2.16%Mkt cap $2.4BP/E (FY) 7.9×1Y +17.8%Off 52W high −15.1%Vol (1Y) 47.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.3% of sh out |
| Days to cover6.0d |
| 13F net flow (QoQ)+8.78% |
| Top-10 13F concentration49.5% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)7.9× |
| Sales (TTM)$885.7M |
| Earnings (TTM)-$458.0M |
| Net margin30.2% |
| Total debt / EBITDA0.00× |
| Sales growth 3Y47.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+22.2% |
| 1Y+17.8% |
| 3Y+29.0% |
| 5Y−43.1% |
| 10Y+163.3% |
| Since incept. (ann.)+2.7% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)47.0% |
| Ann. volatility (3Y)57.3% |
| Sharpe (1Y)0.54 |
| Sharpe (3Y)0.41 |
| Max drawdown (1Y)−28.5% |
| Max drawdown (3Y)−46.2% |
| Beta (3Y vs SPY)0.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 22.7M | $216M | 8.91% | +7.2% |
| RA CAPITAL MANAGEMENT, L.P. | 15.8M | $151M | 6.23% | +0.0% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 15.0M | $143M | 5.92% | +4.9% |
| STATE STREET CORP | 12.2M | $116M | 4.80% | +10.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.2M | $107M | 4.42% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.1M | $106M | 4.38% | new |
| TCG Crossover Management, LLC | 11.0M | $105M | 4.34% | new |
| JANUS HENDERSON GROUP PLC | 8.9M | $85M | 3.51% | +20.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$2.98 | — | $156.4M | +7.5% |
| 2025-12-31 | 2026-02-26 | — | — | $406.6M | +209.1% |
| 2025-09-30 | 2025-11-03 | $0.06 | — | $159.4M | +36.1% |
| 2025-06-30 | 2025-08-04 | $0.02 | — | $163.4M | +49.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
